RADIOTHERAPY
JUST Leveled Up



Watch video

 

Scintix logo

SCINTIX® technology is a novel therapy for patients with tumors in the lung or bone arising from primary and metastatic cancer. This breakthrough technology uses live, continuously updated data throughout the entire treatment session to determine where to deliver radiotherapy.

DOWNLOAD WHITEPAPER

A BREAKOUT ROLE FOR
RADIOPHARMACEUTICALS

Initially cleared to use with fludeoxyglucose F18 (FDG), SCINTIX therapy is the only platform that can leverage the rapidly expanding universe of novel radiopharmaceuticals to more accurately target cancer over other imaging modalities.

METASTATIC DISEASE.
GAME ON.

SCINTIX therapy can treat tumors in the lung or bone from any stage of cancer with conformal dose delivery and potentially smaller margins, resulting in less toxicity that should improve patient outcomes.

MOTION.
MANAGED.

Our SCINTIX technology tracks both periodic and non-periodic tumor motion caused by physiologic processes, and motion you don’t expect, like that from surprise shifts in patient position.

NOW CANCER CAN
DESTROY ITSELF

The RefleXion® X1 with SCINTIX technology marries PET and CT, proven modalities for visualizing cancer, with radiotherapy, one of the most effective ways of treating cancer, in a dual-treatment modality platform.

RefleXion Explainer

By combining radiotherapy and PET-CT in a novel way,
we can find and treat cancer using its own emissions.

RefleXion Overview

Learn more about SCINTIX biology-guided radiotherapy and RefleXion’s vision.

SCINTIX Therapy for Metastatic Disease

See how SCINTIX therapy expands radiotherapy to metastatic patients.

Machine Overview

Take a deeper dive into the RefleXion X1 platform.

WHAT IS SCINTIX THERAPY FROM REFLEXION?

SCINTIX THERAPY LIGHTS UP AND TREATS CANCER IN REAL TIME

SCINTIX therapy uses PET – the gold standard in cancer imaging – in a new way to solve the conundrum of tumor motion. A single radiopharmaceutical injection turns each cancer into a biological beacon that communicates data about the cancer’s location, via a continuous stream of emissions. As the tracer accumulates in tumors, onboard PET detectors on the X1 machine sense the emissions and use this data to deliver treatment with sub-second latency.

Watch Video

ADVANCED-STAGE DISEASE

METASTATIC MEET YOUR MATCH

For cancer patients with tumors in the lung or bone, SCINTIX biology-guided radiotherapy creates a new treatment option. SCINTIX therapy brings the cost effectiveness and efficacy of radiotherapy to more advanced staged cancers. Because SCINTIX technology uses tumor emissions created during treatment to control delivery, clinicians no longer construct plans for moving tumors using an ITV approach that irradiates a large volume. Instead, the PTV may be more conformal to spare healthy tissue and preserve dose for additional tumors.

WATCH VIDEO

DISEASE-SPECIFIC RADIOTRACERS

A BREAKTHROUGH ROLE FOR RADIOTRACERS

SCINTIX biology-guided radiotherapy elevates the performance of radiopharmaceuticals from a diagnostic tool to one that precisely controls treatment delivery. Initially compatible with FDG, RefleXion seeks to enable SCINTIX therapy for other disease-specific tracers. We have forged collaboration agreements with industry-leading radiopharmaceutical manufacturers to develop both fluorine and gallium PSMA tracers that will one day expand SCINTIX therapy to include all stages of prostate cancer.

WATCH VIDEO

A PERFECT FIT

FIRST AND ONLY DUAL-TREATMENT MODALITY PLATFORM

The RefleXion X1 with SCINTIX therapy is the only hybrid platform offering both biologic technology for tumors in motion and anatomic capabilities via its onboard fan-beam kVCT. The X1 fits in most standard vaults with minimum shielding requirements to reduce the implementation and start-up costs.

WATCH VIDEO

Discover the RefleXion X1 platform.

A closer look at the proprietary technologies that combine to create our game-changing approach to cancer treatment.

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up